

1 Poor antibody response to BioNTech/Pfizer COVID-19 vaccination 2 in SARS-CoV-2 naïve residents of nursing homes

3

4 ***Authors list***

5 Pieter Pannus^{1,‡}, Ph.D., Kristof Y Neven^{1,‡}, Ph.D., Stéphane De Craeye², Ph.D., Leo Heyndrickx³,
6 M.Sc., Sara Vande Kerckhove², M.Sc., Daphnée Georges^{4,5}, M.Sc., Johan Michiels³, B.Sc., Antoine
7 Francotte², M.Sc., Marc Van Den Bulcke¹, Ph.D., Maan Zrein⁶, PhD, Steven Van Gucht², Ph.D., Marie-
8 Noëlle Schmickler⁷, M.D., Mathieu Verbrugge⁷, Ph.D., André Matagne⁵, Ph.D., Isabelle Thomas²,
9 Ph.D., Katelijne Dierick², D.M.V., Joshua A. Weiner⁸, Ph.D., Margaret E. Ackerman⁸, Ph.D., Stanislas
10 Goriely⁴, M.D., Maria E Goossens^{1,*}, M.D., Kevin K. Ariën^{3,9,*}, Ph.D., Isabelle Desombere^{2,*}, Ph.D.,
11 Arnaud Marchant^{4*}, M.D.

12

13 ‡ P. P. and K. Y. N. contributed equally to this article.

14 * M.E.G., K.K.A., I.D. and A.M. contributed equally to this article.

15

16 ***Authors affiliations***

17 1 SD Epidemiology and Public Health, Sciensano, Anderlecht, Belgium.

18 2 SD Infectious Diseases in Humans, Sciensano, Ukkel, Belgium.

19 3 Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.

20 4 Institute for Medical Immunology and ULB Center for Research in Immunology (U-CRI), Université
21 libre de Bruxelles (ULB), Gosselies, Belgium.

22 5 Laboratory of Enzymology and Protein Folding, Centre for Protein Engineering, InBioS, University of
23 Liège, Liège, Belgium.

24 6 InfYnity Biomarkers, Lyon, France.

25 7 Mensura EDPB, Occupational Health Service, Antwerp, Belgium.

26 8 Thayer School of Engineering, Dartmouth College, Hanover, NH 03755 USA.

27 9 Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.

28

29 ***Keywords***

30 COVID-19; mRNA vaccination; antibody response; nursing homes; immunosenescence

31 ***Running title***

32 COVID-19 vaccination in nursing homes

33

34 ***Summary***

35 Poor antibody responses to COVID-19 mRNA vaccination were observed in SARS-CoV-2 infection
36 naïve residents and some naïve staff members of nursing homes. This suggests suboptimal protection
37 against breakthrough infection, especially with variants of concern, and the need for adapted
38 vaccination regimens.

39

40 ***Corresponding author***

41 Arnaud Marchant, Institute for Medical Immunology, Campus Erasme, 808 Route de Lennik, 1070
42 Bruxelles, Belgium. Email: arnaud.marchant@ulb.be

43

44 ***Alternate corresponding author***

45 Pieter Pannus, SD Epidemiology and Public Health, Sciensano, 1 Blerotstraat, 1070 Anderlecht,
46 Belgium. Email: pieter.pannus@sciensano.be

47 **Abstract**

48 **Background**

49 Residents of nursing homes (NH) are at high risk of COVID-19 related morbidity and death and may
50 respond poorly to vaccination because of old age and frequent comorbidities.

51

52 **Methods**

53 Forty residents and forty staff members either naïve or previously infected with SARS-CoV-2 were
54 recruited in two NH in Belgium before immunization with two doses of 30µg BNT162b2 mRNA vaccine
55 at day 0 and day 21. Binding antibodies (Ab) to SARS-CoV-2 receptor binding domain (RBD), spike
56 domains S1 and S2, RBD Ab avidity, and neutralizing Ab against SARS-CoV-2 wild type and B.1.351
57 variant were assessed at days 0, 21, 28, and 49.

58

59 **Results**

60 SARS-CoV-2 naïve residents had lower Ab responses to BNT162b2 mRNA vaccination than naïve
61 staff. These poor responses involved lower levels of IgG to all domains of the vaccine antigen, lower
62 avidity of RBD IgG, and lower levels of Ab neutralizing the vaccine strain. No naïve resident had
63 detectable neutralizing Ab to the B.1.351 variant. High and comparable Ab responses were observed
64 in residents and staff previously infected with SARS-CoV-2. Clustering analysis revealed that poor
65 vaccine responders not only included naïve residents but also naïve staff, emphasizing the
66 heterogeneity of responses to mRNA vaccination in the general population.

67

68 **Conclusions**

69 The poor Ab responses to mRNA vaccination observed in infection naïve residents and in some naïve
70 staff members of NH suggest suboptimal protection against breakthrough infection, especially with
71 variants of concern. Adapted vaccination regimens may be needed to provide optimal protection
72 against COVID-19 to vulnerable populations.

73 Introduction

74 Residents of nursing homes (NH) are at a disproportionately high risk of COVID-19 related morbidity
75 and mortality, representing about 5% of all cases while accounting for >30% of all COVID-19 related
76 deaths in the United States [1,2]. Vaccination campaigns around the world have therefore generally
77 prioritized NHs, achieving high coverage rates especially among residents [3,4]. As a result, new
78 cases and deaths have declined steeply in such facilities, outpacing national rates [5–7].

79

80 The success of COVID-19 mRNA vaccination in NH is consistent with data from phase 2 studies
81 indicating potent immunogenicity of these vaccines in younger and older adults [8,9]. However, recent
82 observational studies have found lower antibody (Ab) responses to BNT162b2 vaccination in older
83 adults [10–12]. In addition, chronic comorbidities such as type 2 diabetes and cardiovascular disease
84 were associated with lower vaccine responses [11,13]. These data raise the concern that NH
85 residents, who are old, frail, and often have comorbidities, might respond more poorly to COVID-19
86 vaccination. Supporting this concern, a retrospective observational cohort study from Denmark found
87 lower vaccine effectiveness in NH residents (64%) as compared to healthcare workers (90%) one
88 week after the second dose of BNT162b2 mRNA vaccination [14].

89

90 Decreased efficacy of COVID-19 vaccination in NH residents may be particularly problematic in the
91 face of emerging SARS-CoV-2 variants that are less susceptible to vaccine-induced neutralizing Ab
92 [15–17]. Breakthrough infections with SARS-CoV-2 variants following complete mRNA vaccination
93 have been reported in healthy adults and more recently, severe COVID-19 and death have been
94 reported following an outbreak of the SARS-CoV-2 R.1 variant in a NH in Kentucky [18,19]. The
95 concern of severe breakthrough infection with SARS-CoV-2 variants may be lower in NH residents
96 who have survived natural infection. Indeed, COVID-19 mRNA vaccination induces higher Ab
97 responses in previously infected adults as compared to infection naïve adults and boosts neutralizing
98 Ab cross-reacting with variants of concern [20–25]. The level of cross-reactive immunity induced by
99 mRNA vaccination in naïve and previously infected NH residents is currently unclear.

100

101 Taken together, available data raise concern regarding immunity induced by current COVID-19 mRNA
102 vaccine regimens in infection naïve and frail NH residents, especially in the current context of
103 emerging SARS-CoV-2 variants. We therefore established a longitudinal cohort of SARS-CoV-2 naïve

104 or previously infected NH residents and staff who received two doses of the BNT162b2 mRNA vaccine
105 and assessed the magnitude and quality of Ab responses to SARS-CoV-2 Wuhan (wild type, WT) and
106 B.1.351, first identified in South Africa, as a prototype variant of concern.

107

108 **Material and methods**

109 **Study design and approvals**

110 This study is nested in a prospective cohort study named PICOV (Prior Infection with SARS-CoV-2)
111 [26]. The objective of this nested study was to measure the immune response to SARS-CoV-2 mRNA
112 vaccination in naïve and previously infected residents and members of staff. The study was approved
113 by the Ethics Committee of the Hôpital Erasme, Brussels, Belgium (reference B4062020000134), the
114 Federal Agency for Medicines and Health Products (2021-000401-24), and is registered on
115 ClinicalTrials.gov (NCT04527614).

116

117 **Recruitment and clinical sample collection**

118 SARS-CoV-2 infection-naïve and previously infected residents and staff from two Belgian NHs were
119 recruited. Those with a documented positive RT-qPCR or serological test result at baseline were
120 considered to be previously infected with SARS-CoV-2. Main exclusion criteria for NH residents
121 included a previous diagnosis of dementia, a mini-mental state examination (MMSE) score $\leq 18/30$,
122 and life expectancy < 6 months. As described previously, scores from the Clinical Frailty Scale (CFS)
123 and Quality of Life (QoL) were determined for residents at baseline [26].

124

125 All subjects were immunized with two doses of 30 μ g BNT162b2 mRNA from BioNTech/Pfizer
126 (Comirnaty®), 21 days apart. Blood samples were collected on the day of the primary dose (baseline
127 or day 0), the day of the boost (day 21) as well as one and four weeks after the boost (respectively
128 day 28 and day 49). Serum was separated by blood centrifugation at 1000g for 10 minutes and stored
129 at -20°C for downstream Ab analyses.

130

131 **SARS-CoV-2-Specific Binding Antibodies**

132 Levels of serum Ab were assessed using a multiplexed immunoassay (Multi-SARS-CoV-2
133 Immunoassay), developed in collaboration with InfYnity Biomarkers (Lyon, France). In this microarray,
134 SARS-CoV-2 antigens, selected for their individual performance, were printed in 96-well polystyrene

135 microplates using a sciFLEXARRAYER printing system (Scienion, Germany). Individual SARS-CoV-2
136 antigens, including Spike 1 domain (S1, encompassing AA16-685 of S), Spike 2 domain (S2,
137 encompassing AA686-1213 of S), and Receptor Binding Domain (RBD), were printed in duplicate
138 (GenBank YP009724390.1). Serial dilutions of test samples as well as positive and negative control
139 sera were incubated in microarray plates for 1h at room temperature (RT) and washed with
140 phosphate-buffered saline with 0.05% Tween 20 (PBST). Next, plates were incubated (1h, RT) with
141 horseradish peroxidase-conjugated goat anti-human IgG and washed with PBST before adding a
142 precipitating TMB solution for 20min (RT, dark). Then, TMB was removed and plates were dried at
143 37°C for 10min. Microplates were imaged and analyzed using a microplate reader (SciReader CL,
144 Scienion, Germany). The average pixel intensity for each spot was calculated for each antigen/dilution
145 and reported as net intensity. The dynamic range of each antigen measurement was defined using
146 serial dilutions of positive sera. Only antigen measurements within the dynamic range were
147 considered and were multiplied by the dilution factor. For each serum, quantitative results were eligible
148 if at least 2 dilutions report comparable results (%CV<28%). Results are reported as arbitrary pixel
149 units per milliliter (AU/ml). ROC-analyses using an independent population for validation generated
150 cutoff concentrations of 21.0 AU/ml, 19.5 AU/ml and 19.5 AU/ml for RBD, S1 and S2, respectively
151 (**Supplementary methods**).

152

153 **SARS-CoV-2 Neutralizing Antibodies**

154 Serial dilutions of heat-inactivated serum (1/50-1/25600 in EMEM supplemented with 2mM L-
155 glutamine, 100U/ml - 100µg/ml of Penicillin-Streptomycin and 2% fetal bovine serum) were incubated
156 during 1h (37°C, 7% CO₂) with 3xTCID₅₀ of (i) a wild type (WT) Wuhan strain (2019-nCoV-Italy-
157 INMI1, reference 008V-03893) and (ii) the B.1.351 variant of SARS-CoV-2, in parallel. Sample-virus
158 mixtures and virus/cell controls were added to Vero cells (18.000 cells/well) in a 96-well plate and
159 incubated for five days (37°C, 7% CO₂). The cytopathic effect caused by viral growth was scored
160 microscopically. The Reed-Muench method was used to calculate the neutralizing Ab titer that
161 reduced the number of infected wells by 50% (NT50), which was used as a proxy for the neutralizing
162 Ab concentration in the sample [27].

163

164 **SARS-CoV-2 RBD-Specific antibody avidity**

165 Bio-layer interferometry measurements were performed with an Octet HTX instrument (Fortébio) using
166 AR2G biosensors. Data analyses were performed using FortéBio Data Analysis 9.0 software. Kinetic
167 assays were performed at 25-30°C at a sample plate agitation speed of 1000rpm. Sensors were first
168 activated by immersion in a solution containing 20mM EDC and 10mM s-NHS. Then, 0.05mg/ml of
169 RBD antigen in 10mM sodium acetate pH 6 was loaded for 600sec. After antigen loading, the
170 biosensors were immersed in a solution of 1M ethanolamine pH8.5 to prevent non-specific
171 interactions. Antigen loaded AR2G sensors were first dipped in PBS to establish a baseline time
172 curve, and then immersed for 10min in wells containing purified serum IgG at three different dilutions
173 (3-5-8x). Following IgG association, dissociation was monitored for 600sec in PBS. Negative controls
174 included ligand without IgG and IgG without ligand. Kinetic parameters were determined by global
175 fitting of the association and dissociation phases of the binding curves according to a 1:1 binding
176 model.

177

178 **Statistical analyses**

179 Analyses were performed in R (version 4.0.3). Categorical data were presented as frequencies and
180 percentages, continuous data as means (SD). The Kruskal-Wallis test and post-hoc Mann-Whitney U
181 test alongside multiple testing correction with the false discovery rate were used for all time wise group
182 comparisons. The Mann-Whitney test was used to compare WT and B.1.351 variant neutralizing Ab at
183 day 49. Spearman's rank correlation coefficients (ρ) were determined for associations between
184 WT and B.1.351 variant neutralizing Ab, SARS-CoV-2 binding Ab, and Ab avidity.

185

186 A Uniform Manifold Approximation and Projection (UMAP) analysis was performed using the R
187 package "umap" for dimensionality reduction of the following outcomes at day 49: anti-RBD/S1/S2
188 IgG, anti-RBD IgG avidity, and WT NT50. To achieve normality, avidity was \log_{10} and neutralization
189 \log_2 transformed. The optimal number of clusters was tested via the k-means (range 1:10) and visually
190 identified with an "elbow" in a plot of variance versus number of clusters. DBSCAN ("dbscan" package)
191 identified clusters within the UMAP reduced dimensions.

192

193 **Results**

194 The study included 40 residents and 40 members of staff who were either naïve or previously infected
195 with SARS-CoV-2 before they received 2 x 30µg BNT162b2 mRNA vaccine at their respective NH. In

196 previously infected subjects, SARS-CoV-2 infection occurred between 269 and 315 days before
197 vaccination. Complete cohort and demographic information is provided in **Table 1**. Although residents
198 with the poorest health status were excluded, most enrolled residents were frail and many suffered
199 multiple co-morbidities requiring medication.

200

201 Levels of binding Ab to SARS-CoV-2 spike receptor binding domain (RBD), spike subunit domains
202 one (S1) and two (S2) were measured in longitudinal serum samples using a multiplex immunoassay.
203 Detailed numerical data are presented in **Tab.S1**. At baseline, naïve staff and residents had
204 undetectable levels of SARS-CoV-2-specific IgG whereas high levels of Ab were detected in
205 previously infected subjects (**Fig.1a, Fig.S1**). Primary vaccination induced a significant increase in
206 SARS-CoV-2 Ab in naïve as well as previously infected staff and residents, and Ab levels were further
207 boosted following secondary vaccination at day 21 (**Fig.1a**). Vaccine-induced Ab levels to RBD and
208 S1 were about six-fold lower in naïve residents as compared to naïve staff following primary
209 vaccination and two-fold lower after booster vaccination (**Fig.1b**). In comparison to naïve subjects, Ab
210 levels were strongly increased in both residents and staff previously infected with SARS-CoV-2
211 (**Fig.1b and Fig.S1**). Among previously infected subjects, residents had higher Ab responses to RBD
212 and S1 as compared to staff. Ab responses to S2 were lower than responses to RBD and S1,
213 especially in naïve subjects.

214

215 The avidity of RBD-specific Ab was measured using bio-layer interferometry. Rapid avidity maturation
216 was observed after primary vaccination in naïve and previously infected staff (**Fig.2a**). High RBD IgG
217 avidity was also observed in previously infected residents at day 21, whereas avidity could only be
218 assessed in few naïve residents who had sufficiently high levels of RBD Ab to be characterized
219 (**Fig.2a**). Following booster vaccination, RBD IgG avidity further increased in naïve staff and residents,
220 but remained stable in previously infected subjects (**Fig.2a**). Four weeks after booster vaccination (day
221 49), Ab avidity was significantly higher in naïve staff as compared to naïve residents, and was higher
222 in previously infected subjects as compared to naïve subjects (**Fig.2b**).

223

224 The lower levels and avidity of vaccine-induced Ab observed in naïve residents as compared to naïve
225 staff suggested lower neutralizing Ab capacity. To explore this possibility, titers of neutralizing Ab
226 against WT Wuhan strain and B.1.351 variant were measured. Previously infected staff and residents

227 had detectable neutralizing Ab to the Wuhan strain at baseline and these titers further increased by
228 primary and booster vaccinations (**Fig.2c**). Potent neutralizing Ab responses were also induced by
229 vaccination of naïve staff, although the proportion of subjects with detectable responses decreased
230 between day 28 (18/19) and day 49 (14/19). In contrast, only 6/20 naïve residents had detectable
231 neutralizing Ab at day 28 and this proportion increased to 9/20 at day 49 (**Fig.2c**). At day 49, naïve
232 residents had significantly lower neutralizing Ab responses as compared to naïve staff, whereas
233 higher responses were detected in previously infected subjects as compared to naïve subjects
234 (**Fig.2d**). Compared to the wild type strain, neutralizing titers against the B.1.351 variant were reduced
235 five to ten-fold across study groups (**Fig.2e**). In naïve subjects, only 2/19 staff and none of the naïve
236 residents had detectable neutralizing Ab against the B.1.351 variant at day 49, whereas neutralizing
237 Ab were detected in 19/21 previously infected staff and 18/20 previously infected residents.

238

239 The consistent differences in Ab responses observed between the four study groups suggested a
240 coordinated response to mRNA vaccination across the measured immunological parameters. Indeed,
241 titers of neutralizing Ab against the wild type strain strongly correlated with RBD, S1 and S2 binding
242 Ab, RBD IgG avidity, and neutralizing Ab to the B.1.351 variant (**Fig.2f**).

243

244 To further explore inter-individual variability of this coordinated response, a clustering analysis was
245 performed to reduce the complete dataset to two dimensions and identify groups of subjects who have
246 similar profiles of Ab responses. Five clusters of study participants with distinct Ab levels, avidity, and
247 neutralizing activity at day 49 were identified (**Fig.3a-d**). These clusters were not correlated with age
248 of the study participants (**Fig.3e**). Clusters 4 and 5 exclusively contained previously infected subjects
249 with high Ab responses. Interestingly, cluster 5, including the highest Ab responses, was mostly
250 composed of previously infected residents. In contrast, cluster 1, including the lowest Ab responses,
251 was composed of a mix of naïve residents and naïve staff, indicating that both populations contain low
252 responders to mRNA vaccination. Clusters 2 and 3 included intermediate Ab responses and were
253 composed of a mix of naïve residents, naïve staff and some previously infected staff and residents.
254 The clustering analysis therefore revealed a group of poor Ab responders that not only included naïve
255 residents but also naïve staff.

256

257 **Discussion**

258 Reports on lower Ab responses to COVID-19 mRNA vaccination in older people and in people with
259 chronic comorbidities raise concern about the susceptibility of NH residents to severe breakthrough
260 infections, especially with SARS-CoV-2 variants of concern [10–13]. In this study, NH residents
261 without previous SARS-CoV-2 infection had lower Ab responses to BNT162b2 mRNA vaccination as
262 compared to naïve staff. These defective responses included lower levels of IgG to all domains of the
263 vaccine antigen, lower avidity of RBD IgG and lower levels of neutralizing Ab. Worryingly, none of the
264 naïve residents had detectable neutralizing Ab to the B.1.351 variant.

265

266 Although an immune correlate of protection against COVID-19 has not been established yet, levels of
267 virus-specific binding and neutralizing Ab have been shown to correlate with vaccine efficacy in phase
268 3 studies across different vaccination platforms [28]. In addition, data from pre-clinical studies on non-
269 human primates indicate that mRNA vaccine-induced neutralizing Ab can mediate protection against
270 disease [29–31]. The poor Ab responses observed in our study are therefore likely associated with
271 lower vaccine-induced protection. Providing optimal protection to the vulnerable population of NH
272 residents may require adapted vaccination regimens, such as additional doses of homologous or
273 heterologous vaccines.

274

275 Both age and health status differentiate NH residents and staff. In this cohort, Ab responses were not
276 strongly correlated with age, suggesting a more important role of health status, including frailty and
277 comorbidities. This observation is consistent with the robust Ab responses to mRNA vaccination
278 observed in older people with preserved health status and living outside NH [32]. In both residents and
279 staff, previous SARS-CoV-2 infection was a major determinant of Ab responses, with markedly higher
280 Ab levels and quality in previously infected as compared to naïve subjects. NH residents previously
281 infected with SARS-CoV-2 had remarkably high Ab responses to mRNA vaccination and included the
282 highest responders of the cohort. These high vaccine responses likely reflect potent immunological
283 memory potentially induced by more severe infections and selected by survival after COVID-19 [33]. In
284 marked contrast with naïve residents, NH residents previously infected with SARS-CoV-2 may be at
285 particularly low risk of breakthrough infection following mRNA vaccination.

286

287 Another important finding of this study is that poor vaccine responders were not limited to naïve
288 residents, but also included healthy naïve staff. This observation emphasizes the heterogeneity of Ab

289 responses to mRNA vaccination in the general population [34–36]. As mRNA vaccination has only
290 recently been implemented in large populations, the immunological basis of this heterogeneity is
291 currently unknown. Systems immunology, involving high dimensional analyses of the immune system,
292 is emerging as a promising approach to identify determinants of vaccine responsiveness and has the
293 potential to guide the development of next-generation mRNA vaccines against COVID-19 and other
294 target pathogens [37,38].

295

296 Identifying vulnerable populations who may benefit less from current mRNA vaccination regimens is
297 essential for the control of the COVID-19 pandemic. Adapted mRNA vaccination regimens may be
298 required to protect SARS-CoV-2 naïve residents of NH and younger poor vaccine responders against
299 breakthrough infections, especially with variants of concern.

300 **Acknowledgements**

301 We thank Caroline Rodeghiero, Fabienne Jurion, Elfriede Heerwegh, Giresse Tima, Elisa Brauns,
302 Muriel Nguyen, Séverine Thomas, Vincent Martens, Valérie Acolty, Véronique Olislaghers, Inès Vu
303 Duc, Betty Willems, Maria Lara Escandell, Sandra Coppens, Ann Ceulemans, Koen Bartholomeeusen
304 and Marylène Vandevenne for their technical and logistical help in the laboratory. We thank Martine
305 Delaere, Kristine Massez, Jody Serré, Nathalie Matia Sangrador and Elodie Glinne for their excellent
306 and dedicated work as study nurses. We thank Dr. Piet Maes (Rega Institute, KU Leuven, Belgium) to
307 kindly provide the B.1.351 SARS-CoV-2 isolate. Finally, we thank all residents and members of staff of
308 the participating nursing homes for their availability, flexibility and dedication to the study. S.G. is
309 Senior research Associate and A.M. is Research Director of the FRS-FNRS, Belgium.

310

311 **Financial support**

312 This work was supported by the Belgian Federal Government [COVID-19_SC004, COVID-19_SC049,
313 COVID-19_SC059]; the European Regional Development Fund of the Walloon Region (Wallonia-
314 Biomed portfolio) [411132-957270]; and the Flemish Research Foundation [grant number FWO-
315 G0G4220N to K. K. A.].

316

317 **Potential conflicts of interest**

318 The authors declare no conflicts of interest.

319 References

- 320 1. Werner RM, Hoffman AK, Coe NB. Long-Term Care Policy after Covid-19 - Solving the
321 Nursing Home Crisis. *N Engl J Med* **2020**; 383:903–905.
- 322 2. Apr 23 P, 2021. State COVID-19 Data and Policy Actions. KFF. 2021; Available at:
323 [https://www.kff.org/coronavirus-covid-19/issue-brief/state-covid-19-data-and-policy-](https://www.kff.org/coronavirus-covid-19/issue-brief/state-covid-19-data-and-policy-actions/)
324 [actions/](https://www.kff.org/coronavirus-covid-19/issue-brief/state-covid-19-data-and-policy-actions/). Accessed 27 April 2021.
- 325 3. Dooling K. The Advisory Committee on Immunization Practices' Interim
326 Recommendation for Allocating Initial Supplies of COVID-19 Vaccine — United States,
327 2020. *MMWR Morb Mortal Wkly Rep* **2020**; 69. Available at:
328 <https://www.cdc.gov/mmwr/volumes/69/wr/mm6949e1.htm>. Accessed 27 April 2021.
- 329 4. Gharpure R. Early COVID-19 First-Dose Vaccination Coverage Among Residents and
330 Staff Members of Skilled Nursing Facilities Participating in the Pharmacy Partnership for
331 Long-Term Care Program — United States, December 2020–January 2021. *MMWR*
332 *Morb Mortal Wkly Rep* **2021**; 70. Available at:
333 <https://www.cdc.gov/mmwr/volumes/70/wr/mm7005e2.htm>. Accessed 27 April 2021.
- 334 5. Conlen M, Mervosh S, Ivory D. Nursing Homes, Once Hotspots, Far Outpace U.S. in
335 Covid Declines. *N. Y. Times*. 2021; Available at:
336 <https://www.nytimes.com/interactive/2021/02/25/us/nursing-home-covid-vaccine.html>.
337 Accessed 27 April 2021.
- 338 6. Britton A. Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of
339 Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks — Connecticut,
340 December 2020–February 2021. *MMWR Morb Mortal Wkly Rep* **2021**; 70. Available at:
341 <https://www.cdc.gov/mmwr/volumes/70/wr/mm7011e3.htm>. Accessed 29 April 2021.
- 342 7. Kuehn BM. Israel's Real-life Evidence That Vaccine Can Prevent Severe COVID-19.
343 *JAMA* **2021**; 325:1603–1603.
- 344 8. Walsh EE, Frenck RW, Falsey AR, et al. Safety and Immunogenicity of Two RNA-
345 Based Covid-19 Vaccine Candidates. *N Engl J Med* **2020**; 383:2439–2450.
- 346 9. Anderson EJ, Roupheal NG, Widge AT, et al. Safety and Immunogenicity of SARS-
347 CoV-2 mRNA-1273 Vaccine in Older Adults. *N Engl J Med* **2020**; 383:2427–2438.
- 348 10. Predecki M, Clarke C, Brown J, et al. Effect of previous SARS-CoV-2 infection on
349 humoral and T-cell responses to single-dose BNT162b2 vaccine. *Lancet Lond Engl*
350 **2021**;
- 351 11. Müller L, Andrée M, Moskorz W, et al. Age-dependent immune response to the
352 Biontech/Pfizer BNT162b2 COVID-19 vaccination. *Clin Infect Dis Off Publ Infect Dis*
353 *Soc Am* **2021**;
- 354 12. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a
355 Nationwide Mass Vaccination Setting. *N Engl J Med* **2021**;
- 356 13. Yelin I, Katz R, Herzel E, et al. Associations of the BNT162b2 COVID-19 vaccine
357 effectiveness with patient age and comorbidities. *medRxiv* **2021**;
358 :2021.03.16.21253686.
- 359 14. Moustsen-Helms IR, Emborg H-D, Nielsen J, et al. Vaccine effectiveness after 1st and
360 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term care facility residents

- 361 and healthcare workers – a Danish cohort study. medRxiv **2021**;
362 :2021.03.08.21252200.
- 363 15. Chen RE, Zhang X, Case JB, et al. Resistance of SARS-CoV-2 variants to
364 neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med **2021**;
365 :1–10.
- 366 16. Wang P, Nair MS, Liu L, et al. Antibody Resistance of SARS-CoV-2 Variants B.1.351
367 and B.1.1.7. Nature **2021**; :1–9.
- 368 17. Zhou D, Dejnirattisai W, Supasa P, et al. Evidence of escape of SARS-CoV-2 variant
369 B.1.351 from natural and vaccine-induced sera. Cell **2021**; 184:2348–2361.e6.
- 370 18. Hacisuleyman E, Hale C, Saito Y, et al. Vaccine Breakthrough Infections with SARS-
371 CoV-2 Variants. N Engl J Med **2021**; 0:null.
- 372 19. Teran RA. Postvaccination SARS-CoV-2 Infections Among Skilled Nursing Facility
373 Residents and Staff Members — Chicago, Illinois, December 2020–March 2021.
374 MMWR Morb Mortal Wkly Rep **2021**; 70. Available at:
375 <https://www.cdc.gov/mmwr/volumes/70/wr/mm7017e1.htm>. Accessed 29 April 2021.
- 376 20. Manisty C, Otter AD, Treibel TA, et al. Antibody response to first BNT162b2 dose in
377 previously SARS-CoV-2-infected individuals. Lancet Lond Engl **2021**; 397:1057–1058.
- 378 21. Krammer F, Srivastava K, Alshammary H, et al. Antibody Responses in Seropositive
379 Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med **2021**;
380 384:1372–1374.
- 381 22. Stamatatos L, Czartoski J, Wan Y-H, et al. mRNA vaccination boosts cross-variant
382 neutralizing antibodies elicited by SARS-CoV-2 infection. Science **2021**;
- 383 23. Samanovic MI, Cornelius AR, Wilson JP, et al. Poor antigen-specific responses to the
384 second BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals.
385 MedRxiv Prepr Serv Health Sci **2021**;
- 386 24. Lustig Y, Nemet I, Kliker L, et al. Neutralizing Response against Variants after SARS-
387 CoV-2 Infection and One Dose of BNT162b2. N Engl J Med **2021**; 0:null.
- 388 25. Ebinger JE, Fert-Bober J, Printsev I, et al. Antibody responses to the BNT162b2 mRNA
389 vaccine in individuals previously infected with SARS-CoV-2. Nat Med **2021**;
- 390 26. Outlining the Prior Infection with SARS-CoV-2 study (PICOV) - preliminary findings on
391 symptoms in nursing home residents and staff. 2021. Available at:
392 <https://www.researchsquare.com>. Accessed 9 April 2021.
- 393 27. Mariën J, Ceulemans A, Michiels J, et al. Evaluating SARS-CoV-2 spike and
394 nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19
395 cases using a Luminex bead-based assay. J Virol Methods **2021**; 288:114025.
- 396 28. Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a protective
397 correlate for COVID-19 vaccines. medRxiv **2021**; :2021.03.17.20200246.
- 398 29. Vogel AB, Kanevsky I, Che Y, et al. BNT162b vaccines protect rhesus macaques from
399 SARS-CoV-2. Nature **2021**; 592:283–289.
- 400 30. Corbett KS, Flynn B, Foulds KE, et al. Evaluation of the mRNA-1273 Vaccine against
401 SARS-CoV-2 in Nonhuman Primates. N Engl J Med **2020**; 383:1544–1555.

- 402 31. McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in
403 rhesus macaques. *Nature* **2021**; 590:630–634.
- 404 32. Parry HM, Tut G, Faustini S, et al. BNT162b2 Vaccination in People Over 80 Years of
405 Age Induces Strong Humoral Immune Responses with Cross Neutralisation of P.1
406 Brazilian Variant. Rochester, NY: Social Science Research Network, 2021. Available at:
407 <https://papers.ssrn.com/abstract=3816840>. Accessed 8 April 2021.
- 408 33. Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of
409 asymptomatic SARS-CoV-2 infections. *Nat Med* **2020**; 26:1200–1204.
- 410 34. Keehner J, Horton LE, Pfeffer MA, et al. SARS-CoV-2 Infection after Vaccination in
411 Health Care Workers in California. *N Engl J Med* **2021**; 0:null.
- 412 35. Kustin T, Harel N, Finkel U, et al. Evidence for increased breakthrough rates of SARS-
413 CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals. *medRxiv* **2021**;
414 :2021.04.06.21254882.
- 415 36. COVID-19 Breakthrough Case Investigations and Reporting | CDC. 2021. Available at:
416 <https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html>.
417 Accessed 5 May 2021.
- 418 37. Tsang JS, Dobaño C, VanDamme P, et al. Improving Vaccine-Induced Immunity: Can
419 Baseline Predict Outcome? *Trends Immunol* **2020**; 41:457–465.
- 420 38. Kotliarov Y, Sparks R, Martins AJ, et al. Broad immune activation underlies shared set
421 point signatures for vaccine responsiveness in healthy individuals and disease activity
422 in patients with lupus. *Nat Med* **2020**; 26:618–629.
- 423
- 424

425 **Table 1. Demographic Characteristics of the Participants, According to Study Group.**

| | naive staff (N=19) | naive resident (N=20) | infected staff (N=21) | infected resident (N=20) | Total (N=80) | p value |
|-------------------------------------|-----------------------|--------------------------|-----------------------------|--------------------------------|-----------------|---------|
| Age, years | | | | | | <0.001 |
| Mean (SD) | 47.9 (10.2) | 86.0 (8.3) | 47.6 (11.0) | 84.3 (7.7) | 66.4 (21.0) | |
| Range | 23.0 - 64.0 | 67.0 - 102.0 | 30.0 - 68.0 | 65.0 - 94.0 | 23.0 - 102.0 | |
| Gender | | | | | | 0.66 |
| Female | 14 (73.7%) | 13 (65.0%) | 16 (76.2%) | 12 (60.0%) | 55 (68.8%) | |
| Male | 5 (26.3%) | 7 (35.0%) | 5 (23.8%) | 8 (40.0%) | 25 (31.2%) | |
| Ethnicity | | | | | | 0.13 |
| Caucasian | 17 (89.5%) | 20 (100.0%) | 18 (85.7%) | 20 (100.0%) | 75 (93.8%) | |
| Other | 2 (10.5%) | 0 (0.0%) | 3 (14.3%) | 0 (0.0%) | 5 (6.2%) | |
| BMI, kg/m² * | | | | | | 0.009 |
| Mean (SD) | 27.3 (5.3) | 24.8 (6.0) | 28.1 (5.3) | 22.9 (4.3) | 25.8 (5.6) | |
| Range | 21.2 - 36.8 | 16.7 - 36.3 | 20.1 - 44.2 | 14.6 - 30.5 | 14.6 - 44.2 | |
| Self-reported smoking status | | | | | | 0.48 |
| Ex-smoker | 1 (5.3%) | 1 (5.0%) | 3 (14.3%) | 5 (25.0%) | 10 (12.5%) | |
| Non-smoker | 16 (84.2%) | 18 (90.0%) | 17 (81.0%) | 14 (70.0%) | 65 (81.2%) | |
| Current smoker | 2 (10.5%) | 1 (5.0%) | 1 (4.8%) | 1 (5.0%) | 5 (6.2%) | |
| Daily exercise | | | | | | 0.005 |
| less than 30 minutes | 3 (15.8%) | 12 (60.0%) | 2 (9.5%) | 10 (50.0%) | 27 (33.8%) | |
| 30 to 60 minutes | 6 (31.6%) | 6 (30.0%) | 7 (33.3%) | 6 (30.0%) | 25 (31.2%) | |
| at least 60 minutes | 9 (47.4%) | 2 (10.0%) | 12 (57.1%) | 3 (15.0%) | 26 (32.5%) | |
| None | 1 (5.3%) | 0 (0.0%) | 0 (0.0%) | 1 (5.0%) | 2 (2.5%) | |
| Self-reported health status | | | | | | <0.001 |
| Very good health | 9 (47.4%) | 0 (0.0%) | 4 (19.0%) | 2 (10.0%) | 15 (18.8%) | |
| Good health | 10 (52.6%) | 12 (60.0%) | 14 (66.7%) | 8 (40.0%) | 44 (55.0%) | |
| Reasonable health | 0 (0.0%) | 8 (40.0%) | 2 (9.5%) | 9 (45.0%) | 19 (23.8%) | |
| Bad health | 0 (0.0%) | 0 (0.0%) | 1 (4.8%) | 1 (5.0%) | 2 (2.5%) | |
| Quality of Life index | | | | | | <0.001 |
| Mean (SD) | 0.9 (0.1) | 0.6 (0.3) | 0.8 (0.2) | 0.6 (0.2) | 0.7 (0.2) | |
| Range | 0.7 - 1.0 | 0.1 - 1.0 | 0.5 - 1.0 | 0.2 - 1.0 | 0.1 - 1.0 | |
| Medication use | | | | | | |
| Cardiovascular disease | 1 (5.3%) | 17 (85.0%) | 1 (4.8%) | 19 (95.0%) | 38 (47.5%) | <0.001 |
| Hypertension | 2 (10.5%) | 14 (70.0%) | 3 (14.3%) | 19 (95.0%) | 38 (47.5%) | <0.001 |
| Pain medication | 0 (0.0%) | 15 (75.0%) | 0 (0.0%) | 12 (60.0%) | 27 (33.8%) | <0.001 |
| Diabetes Mellitus | 0 (0.0%) | 4 (20.0%) | 0 (0.0%) | 3 (15.0%) | 7 (8.8%) | 0.05 |
| Anti-psychotic medication | 0 (0.0%) | 10 (50.0%) | 0 (0.0%) | 8 (40.0%) | 18 (22.5%) | <0.001 |
| Anti-depressant medication | 0 (0.0%) | 12 (60.0%) | 0 (0.0%) | 7 (35.0%) | 19 (23.8%) | <0.001 |
| Pulmonary disease | 0 (0.0%) | 3 (15.0%) | 0 (0.0%) | 1 (5.0%) | 4 (5.0%) | 0.10 |
| Allergy | 0 (0.0%) | 2 (10.0%) | 0 (0.0%) | 3 (15.0%) | 5 (6.2%) | 0.12 |
| Neurological disease | 0 (0.0%) | 4 (20.0%) | 0 (0.0%) | 2 (10.0%) | 6 (7.5%) | 0.05 |
| Immunological disease | 0 (0.0%) | 0 (0.0%) | 1 (4.8%) | 0 (0.0%) | 1 (1.2%) | 0.42 |
| MMSE score[†] | | | | | | 0.98 |
| Mean (SD) | . | 25.6 (3.2) | . | 25.9 (3.3) | 25.8 (3.2) | |
| Range | . | 19.0 - 30.0 | . | 18.0 - 30.0 | 18.0 - 30.0 | |
| Frailty scale[†] | | | | | | |
| Very fit | . | 0 (0.0%) | . | 1 (5.0%) | 1 (2.5%) | 0.40 |
| Fit | . | 3 (15.0%) | . | 1 (5.0%) | 4 (10.0%) | 0.28 |
| Managing well | . | 5 (25.0%) | . | 7 (35.0%) | 12 (30.0%) | 0.87 |
| Very mild frailty | . | 3 (15.0%) | . | 3 (15.0%) | 6 (15.0%) | 1.00 |
| Mild frailty | . | 6 (30.0%) | . | 4 (20.0%) | 10 (25.0%) | 0.55 |
| Moderate frailty | . | 1 (5.0%) | . | 3 (15.0%) | 4 (10.0%) | 0.47 |
| Severe frailty | . | 2 (10.0%) | . | 1 (5.0%) | 3 (7.5%) | 0.39 |

426 *Data are mean (SD) or n (%). Range denotes the lowest to the highest numerical observation.*

427 ** Data available for 19, 19, 21, 20, and 79 subjects.*

428 *† Mini-mental State Examination (MMSE) and Frailty scale was only asked to residents.*

429

430

431 **Figure legends**

432

433 **Figure 1. SARS-CoV-2 Specific Binding Antibody Responses to BNT162b2 mRNA Vaccination**
434 **in Residents and Staff of Nursing Homes.**

435 SARS-CoV-2 naïve and previously infected NH residents and staff received two doses of 30µg
436 BNT162b2 vaccine on day 0 and day 21 (arrows). The concentration of spike-specific binding Ab was
437 measured using a multiplex assay before vaccination and at days 21, 28 and 49 after the first dose
438 and is shown as arbitrary pixel units per ml (AU/ml; limit of quantification, 21.0 for RBD, 19.5 for S1
439 and S2). Each data point represents a serum sample. Statistical significance of differences between
440 time points (**panel A**) and study groups (**panel B**) were determined by the Kruskal-Wallis test by
441 ranks, using the Mann-Whitney U post-hoc test and Benjamini-Hochberg correction for multiple testing
442 (*: $p < 0.05$; **: $p < 0.01$; ***: $p < 0.001$).

443


444 **Figure 2. Low RBD IgG Avidity and Neutralizing Antibody Responses in SARS-CoV-2 Naïve**
445 **Residents.**

446 RBD IgG avidity and neutralizing Ab responses to mRNA vaccination were measured at days 0, 21, 28
447 and 49 in SARS-CoV-2 naïve and previously infected residents and staff. **Panels A and B.** Avidity of
448 RBD-specific IgG (K_{off} in 1/s). 'N tested' indicates the number of participants with sufficiently high
449 antibody concentrations for avidity testing (panel A). **Panels C/D/E.** 50% neutralizing Ab titers of
450 SARS-CoV-2 wild type (WT) and B.1351 variant (lower limit of quantification, LLOQ, 1/50). 'N > LLOQ'
451 indicates the number of participants with detectable neutralizing Ab (panel C). Black bars indicate
452 median values. Statistical significance of differences between time points and study groups were
453 determined by the Kruskal-Wallis test by ranks, using the Mann-Whitney U post-hoc test and
454 Benjamini-Hochberg correction for multiple testing (*: $p < 0.05$; **: $p < 0.01$; ***: $p < 0.001$). For differences
455 between wild type and the B.1.351 variant the Mann-Whitney test was used. **Panel F.** Spearman's
456 rank correlation coefficients (ρ) between titers of neutralizing Ab to WT strain and the other Ab
457 response parameters. Data below or above limits of quantification were excluded (gray dots).

458

459 **Figure 3. Low Vaccine Responders Include both SARS-CoV-2 Naïve Nursing Home Residents**
460 **and Staff.**

461 **Panel A.** Clustering (UMAP) analysis of all study participants with available RBD/S1/S2 binding IgG
462 Ab concentrations, RBD-IgG avidity and SARS-CoV-2 wild type neutralization at day 49. The position
463 of individual participants in variable space 1 and 2 indicates similarities or differences in Ab responses.
464 DBSCAN was used to identify clusters. **Panels B/C/D.** Clusters 1 to 5 are plotted against the RBD
465 binding IgG, RBD IgG avidity and WT neutralizing titers, respectively. **Panel E.** Age of participants
466 included in clusters of antibody responses. Black bars indicate median values.

a Figure 1**b**